HCW Biologics (HCWB) fell nearly 11% in recent Monday trading after the company said it received a delisting notice from Nasdaq.
The company said it faces potential delisting following its failure to regain compliance with Nasdaq's requirements for continued listing. It was notified in June by exchange regulators that its market value of listed securities, or MVLS, was below the required $50 million threshold for 30 straight business days.
HCW Biologics said it intends to timely request a hearing before the Nasdaq Hearing Panel to avoid delisting and to discuss how it plans to regain compliance with the MVLS rule.
Price: 0.40, Change: -0.05, Percent Change: -10.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.